Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.
about
Temozolomide for high grade gliomaTemozolomide for High Grade GliomaExciting new advances in neuro-oncology: the avenue to a cure for malignant gliomaThe Efficacy of Ketogenic Diet and Associated Hypoglycemia as an Adjuvant Therapy for High-Grade Gliomas: A Review of the LiteratureVorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK PathwaysPhase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813.Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors.Initial treatment patterns over time for anaplastic oligodendroglial tumors.Clinical and histological features of idiosyncratic acute liver injury caused by temozolomide.Radiotherapeutic alternatives for previously irradiated recurrent gliomas.Surgical management of high-grade glioma: a standard of care.Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy.Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma.Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme.Temozolomide in paediatric high-grade glioma: a key for combination therapy?A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomasPhase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium studyPhase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant gliomaDose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study.Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial.Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model.Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant gliomaDNA ligase IV as a new molecular target for temozolomidePhase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.Progress on antiangiogenic therapy for patients with malignant glioma.First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response.Rationally designed pharmacogenomic treatment using concurrent capecitabine and radiotherapy for glioblastoma; gene expression profiles associated with outcome.Recurrent high-grade glioma: a diagnostic and therapeutic challenge.Evolution of malignant glioma treatment: from chemotherapy to vaccines to viruses.Prodrug activation enzymes in cancer gene therapy.Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas.Evaluation of O6-methylguanine-DNA methyltransferase enzyme expression effect on survival of patients with Grade 4 brain astrocytomaCentral nervous system cancersBrain tumors in the older person.Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study.Medical therapy of gliomas.Stratification according to HGG-IMMUNO RPA model predicts outcome in a large group of patients with relapsed malignant glioma treated by adjuvant postoperative dendritic cell vaccination.The efficacy of temozolomide for recurrent glioblastoma multiforme.Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD).Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations
P2860
Q24197645-12DB4516-1B3B-49FF-85F9-E62A8FDC7223Q24241222-DE7124FF-BDA2-4D55-B5DC-524BDF36CAABQ24632791-772773D7-45CD-47D8-81AF-4CDA5944AFE4Q26800604-9EE41C15-C6D5-4619-A3E5-8DA0A295DA49Q28550980-34984111-A720-4382-AF61-A40A3BF8F052Q30275188-C4C61843-9649-48CB-ACAD-6BF2BBC219CDQ30417015-7C0322C3-B734-4163-AD95-1B1AF1C3A726Q30419123-AE981AC8-7B10-4B1D-8EBC-8CED50D3543DQ30447260-353198AD-9E04-4FFB-B5AF-735CBDEEDDE8Q30497184-6F3BBF14-879E-44D2-878B-1042236BC31AQ30838365-8E56C292-AD81-4CF7-97E6-89F4F5A69C2BQ30906322-D9FA6D90-FAE5-41D7-AC82-87B304FBFB3CQ33346715-36800F26-59F4-4183-BAB2-0165DE721D9EQ33358912-234EB57B-C34C-4E48-9FF4-69CBE0D884ABQ33361765-0D5EEDD7-585F-4F3C-89EC-BD9BB303209BQ33375377-476B5D15-57B8-4246-A763-ACC84123F2BAQ33377664-CFA0BE84-81C8-4EBB-AB56-95AF675E95ABQ33384269-20FDF434-8673-4320-B1B6-EF20DBE07F18Q33386298-652440D8-00E8-4844-846E-377E2410CFC3Q33439379-A0B9C124-5F92-4C97-975C-773A4D7B5146Q33642356-58A56E0B-3968-46F3-88BE-00C991A36438Q33696343-5C62265E-82AC-494F-889A-5F33FAAAB13AQ33699997-4F3E4303-B391-4558-AE92-FE028588C219Q33713587-E3E76566-F676-480A-BC18-AD97C2E07AEEQ33773189-5B5D0DD6-B8FC-4C15-9302-D8042D177AD4Q33777877-47F4C5D7-411A-40EC-9567-78178A7047D0Q33853588-C87CE81E-591C-431A-B412-18C6040A9415Q33864058-AC524733-1CCA-4961-A8D5-85E18FC840C9Q33923950-0FBDC88F-937B-4FB9-B294-0F2073E5D05AQ33968115-BD4ABF3B-72B5-4DD6-B3CE-C9E1C73335A6Q33973844-CBECE80E-A71E-49F1-BE84-E9AD83AFAD0FQ33977312-49C541F4-5141-40C1-A916-3115F28606FEQ34014740-0BDBAE3F-723C-4BB9-8043-D4F785321B1FQ34087862-897C0D39-C322-46FB-B0E8-82CDC2438455Q34186787-804A091D-2907-497A-B691-D9BD444EBB27Q34218761-774AB4CB-A1E6-4298-9B3E-E386B1432348Q34260758-D3A20778-63B8-49A9-8F91-945FF0EDF4DCQ34297519-30DA914B-F733-43BC-9E89-382DF0D64E84Q34331320-4A7DBCDB-C880-416F-9A26-DBBC19821227Q34418437-BE3B4817-3380-49C7-8961-0AE7E0C57773
P2860
Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Multicenter phase II trial of ...... se. Temodal Brain Tumor Group.
@ast
Multicenter phase II trial of ...... se. Temodal Brain Tumor Group.
@en
type
label
Multicenter phase II trial of ...... se. Temodal Brain Tumor Group.
@ast
Multicenter phase II trial of ...... se. Temodal Brain Tumor Group.
@en
prefLabel
Multicenter phase II trial of ...... se. Temodal Brain Tumor Group.
@ast
Multicenter phase II trial of ...... se. Temodal Brain Tumor Group.
@en
P2093
P1476
Multicenter phase II trial of ...... se. Temodal Brain Tumor Group.
@en
P2093
A H Friedman
A M O'Neill
M D Prados
R Albright
R Yaya-Tur
P304
P356
10.1200/JCO.1999.17.9.2762
P407
P577
1999-09-01T00:00:00Z